APA (7th ed.) Citation

GR, G., M, A., S, B., N, B., F, G., CC, L., . . . J, C. (2024). Considerations for Industry-Preparing for the FDA Model-Informed Drug Development (MIDD) Paired Meeting Program. Clinical pharmacology and therapeutics, 116(2), 282. https://doi.org/10.1002/cpt.3245

Chicago Style (17th ed.) Citation

GR, Galluppi, et al. "Considerations for Industry-Preparing for the FDA Model-Informed Drug Development (MIDD) Paired Meeting Program." Clinical Pharmacology and Therapeutics 116, no. 2 (2024): 282. https://doi.org/10.1002/cpt.3245.

MLA (9th ed.) Citation

GR, Galluppi, et al. "Considerations for Industry-Preparing for the FDA Model-Informed Drug Development (MIDD) Paired Meeting Program." Clinical Pharmacology and Therapeutics, vol. 116, no. 2, 2024, p. 282, https://doi.org/10.1002/cpt.3245.